Search Results - "Peters, Ron J.G."

Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population by Kaasenbrood, Lotte, Boekholdt, S Matthijs, van der Graaf, Yolanda, Ray, Kausik K, Peters, Ron J.G, Kastelein, John J.P, Amarenco, Pierre, LaRosa, John C, Cramer, Maarten J.M, Westerink, Jan, Kappelle, L Jaap, de Borst, Gert J, Visseren, Frank L.J

“…BACKGROUND:Among patients with clinically manifest vascular disease, the risk of recurrent vascular events is likely to vary. We assessed the distribution of…”
Get full text

A multilevel and multicenter assessment of health care system capacity to manage cardiovascular diseases in Africa: a baseline study of the Ghana Heart Initiative by Doku, Alfred, Tuglo, Lawrence Sena, Chilunga, Felix, Edzeame, Juliette, Peters, Ron J.G, Agyemang, Charles

“…Abstract Introduction Cardiovascular diseases (CVD) remain the leading cause of death worldwide, with over 70% of these deaths occurring in low- and…”
Get full text

Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers by Bijsterveld, Nick R, Moons, Arno H, Boekholdt, S Matthijs, van Aken, Benien E, Fennema, Hein, Peters, Ron J G, Meijers, Joost C M, Büller, Harry R, Levi, Marcel

“…The novel anticoagulant fondaparinux proved to be effective and safe in the postoperative prevention of venous thrombosis. Current phase III trials with this…”
Get full text

The role of body weight, fat distribution and weight change in ethnic differences in the 9-year incidence of hypertension by Grootveld, Laura R, Van Valkengoed, Irene G.M, Peters, Ron J.G, Ujcic-Voortman, Joanne K, Brewster, Lizzy M, Stronks, Karien, Snijder, Marieke B

“…OBJECTIVE:To investigate the role of body composition (body weight, fat distribution and weight change over time) in ethnic differences in the incidence of…”
Get full text

Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events by BOEKHOLDT, S. Matthijs, AGEMA, Willem R. P, PETERS, Ron J. G, ZWINDERMAN, Aeilko H, VAN DER WALL, Ernst E, REITSMA, Pieter H, KASTELEIN, John J. P, JUKEMA, J. Wouter

“…Atherosclerosis is increasingly considered to be a chronic inflammatory process. We examined whether genetic variants of the toll-like receptor 4 (TLR4), which…”
Get full text

Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease by Lonn, Eva M, Bosch, Jackie, López-Jaramillo, Patricio, Zhu, Jun, Liu, Lisheng, Pais, Prem, Diaz, Rafael, Xavier, Denis, Sliwa, Karen, Dans, Antonio, Avezum, Alvaro, Piegas, Leopoldo S, Keltai, Katalin, Keltai, Matyas, Chazova, Irina, Peters, Ron J.G, Held, Claes, Yusoff, Khalid, Lewis, Basil S, Jansky, Petr, Parkhomenko, Alexander, Khunti, Kamlesh, Toff, William D, Reid, Christopher M, Varigos, John, Leiter, Lawrence A, Molina, Dora I, McKelvie, Robert, Pogue, Janice, Wilkinson, Joanne, Jung, Hyejung, Dagenais, Gilles, Yusuf, Salim

“…In one comparison from a 2-by-2 factorial trial, over 12,000 participants with a mean baseline blood pressure of 138/82 mm Hg were assigned to candesartan plus…”
Get full text

Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease by Yusuf, Salim, Lonn, Eva, Pais, Prem, Bosch, Jackie, López-Jaramillo, Patricio, Zhu, Jun, Xavier, Denis, Avezum, Alvaro, Leiter, Lawrence A, Piegas, Leopoldo S, Parkhomenko, Alexander, Keltai, Matyas, Keltai, Katalin, Sliwa, Karen, Chazova, Irina, Peters, Ron J.G, Held, Claes, Yusoff, Khalid, Lewis, Basil S, Jansky, Petr, Khunti, Kamlesh, Toff, William D, Reid, Christopher M, Varigos, John, Accini, Jose L, McKelvie, Robert, Pogue, Janice, Jung, Hyejung, Liu, Lisheng, Diaz, Rafael, Dans, Antonio, Dagenais, Gilles

“…In a 2-by-2 factorial trial, 12,705 persons at intermediate risk were assigned to candesartan plus hydrochlorothiazide or placebo and to rosuvastatin or…”
Get full text

Prognostic Value of Access Site and Nonaccess Site Bleeding After Percutaneous Coronary Intervention by Kikkert, Wouter J., MD, Delewi, Ronak, MD, Ouweneel, Dagmar M., MSc, van Nes, Sophie H, Vis, Marije M., MD, PhD, Baan, Jan, MD, PhD, Koch, Karel T., MD, PhD, Dangas, George D., MD, PhD, Mehran, Roxana, MD, de Winter, Robbert J., MD, PhD, Peters, Ron J.G., MD, PhD, Piek, Jan J., MD, PhD, Tijssen, Jan G.P., PhD, Henriques, Jose P.S., MD, PhD

“…Objectives This study sought to investigate the prognostic value of access site bleeding (ASB) and non-ASB for recurrent ischemic outcomes and mortality in…”
Get full text

Creatinine Rise During Blood Pressure Therapy and the Risk of Adverse Clinical Outcomes in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of the ACCORD-BP Randomized Controlled Trial by Collard, Didier, Brouwer, Tom F, Peters, Ron J.G, Vogt, Liffert, van den Born, Bert-Jan H

“…Lowering blood pressure may affect renal function. Current guidelines state that reducing antihypertensive therapy should be considered in patients with a >30%…”
Get full text

Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation: Results From the RE-LY Trial by Stam-Slob, Manon C, Connolly, Stuart J, van der Graaf, Yolanda, van der Leeuw, Joep, Dorresteijn, Jannick A.N, Eikelboom, John W, Peters, Ron J.G, Alings, Marco, Visseren, Frank L.J

“…BACKGROUND:We aimed to estimate absolute benefit and harm from treatment with dabigatran in individual patients with atrial fibrillation, and to select the…”
Get full text

Safety of supervised exercise therapy in patients with intermittent claudication by Gommans, Lindy N.M., MD, MSc, Fokkenrood, Hugo J.P., MD, van Dalen, Hendrika C.W., MSc, Scheltinga, Marc R.M., MD, PhD, Teijink, Joep A.W., MD, PhD, Peters, Ron J.G., MD, PhD

“…Background Supervised exercise therapy (SET) is recommended as the primary treatment for patients with intermittent claudication (IC). However, there is…”
Get full text

Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention : Results from the OASIS-5 trial by MEHTA, Shamir R, GRANGER, Christopher B, FOX, Keith A. A, YUSUF, Salim, EIKELBOOM, John W, BASSAND, Jean-Pierre, WALLENTIN, Lars, FAXON, David P, PETERS, Ron J. G, BUDAJ, Andrzej, AFZAL, Rizwan, CHROLAVICIUS, Susan

“…This study reports a prospectively planned analysis of patients with acute coronary syndrome who underwent early percutaneous coronary intervention (PCI) in…”
Get full text

Effects of aspirin dose when used alone or in combination with Clopidogrel in patients with acute coronary syndromes: Observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study by PETERS, Ron J. G, MEHTA, Shamir R, FOX, Keith A. A, FENG ZHAO, LEWIS, Basil S, KOPECKY, Steven L, DIAZ, Rafael, COMMERFORD, Patrick J, VALENTIN, Vicent, YUSUF, Salim

“…We studied the benefits and risks of adding clopidogrel to different doses of aspirin in the treatment of patients with acute coronary syndrome (ACS). In the…”
Get full text

Ethnic disparities in treatment rates for hypertension and dyslipidemia: an analysis by different treatment indications: the Healthy Life in an Urban Setting study by Perini, Wilco, Agyemang, Charles, Snijder, Marieke B, Peters, Ron J.G, Kunst, Anton E

“…BACKGROUND:Studies have reported ethnic disparities in treatment rates for cardiovascular risk factors. These studies are generally based on treatment…”
Get full text

Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease by Yusuf, Salim, Bosch, Jackie, Dagenais, Gilles, Zhu, Jun, Xavier, Denis, Liu, Lisheng, Pais, Prem, López-Jaramillo, Patricio, Leiter, Lawrence A., Dans, Antonio, Avezum, Alvaro, Piegas, Leopoldo S., Parkhomenko, Alexander, Keltai, Katalin, Keltai, Matyas, Sliwa, Karen, Peters, Ron J.G., Held, Claes, Chazova, Irina, Yusoff, Khalid, Lewis, Basil S., Jansky, Petr, Khunti, Kamlesh, Toff, William D., Reid, Christopher M., Varigos, John, Sanchez-Vallejo, Gregorio, McKelvie, Robert, Pogue, Janice, Jung, Hyejung, Gao, Peggy, Diaz, Rafael, Lonn, Eva

Get full text

Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes by Budaj, Andrzej, Eikelboom, John W., Mehta, Shamir R., Afzal, Rizwan, Chrolavicius, Susan, Bassand, Jean-Pierre, Fox, Keith A.A., Wallentin, Lars, Peters, Ron J.G., Granger, Christopher B., Joyner, Campbell D., Yusuf, Salim

“…Aims Bleeding in patients with coronary artery disease has been linked with adverse outcomes. We examined the incidence and outcomes after bleeding in 20 078…”
Get full text

Prevalence of Cardiovascular Disease and Risk Factors in Ghana: A Systematic Review and Meta-analysis by Doku, Alfred, Tuglo, Lawrence Sena, Boima, Vincent, Agyekum, Francis, Aovare, Pearl, Ali Abdulai, Martha, Godi, Anthony, Peters, Ron J G, Agyemang, Charles

“…The increasing cardiovascular disease (CVD) burden threatens the global population as the major cause of disability and premature death. Data are scarce on the…”
Get full text

Ethnic Disparities in CKD in the Netherlands: The Healthy Life in an Urban Setting (HELIUS) Study by Agyemang, Charles, MPH, PhD, Snijder, Marieke B., MSc, PhD, Adjei, David N., MSc, van den Born, Bert-Jan H., MD, PhD, Modesti, Pietro A., MD, PhD, Peters, Ron J.G., MD, PHD, Stronks, Karien, MSc, PhD, Vogt, Liffert, MD, PhD

“…Background Evidence suggesting important ethnic differences in chronic kidney disease (CKD) prevalence comes mainly from the United States, and data among…”
Get full text

Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study by Jolly, Sanjit S., Pogue, Janice, Haladyn, Kimberly, Peters, Ron J.G., Fox, Keith A.A., Avezum, Alvaro, Gersh, Bernard J., Rupprecht, Hans Jurgen, Yusuf, Salim, Mehta, Shamir R.

“…Aims In the setting of percutaneous coronary intervention (PCI), due to a paucity of data, the optimal dose of aspirin is uncertain. We evaluated the safety of…”
Get full text

Patients' preferences for secondary prevention following a coronary event by van Trier, Tinka J., Jørstad, Harald T., Scholte op Reimer, Wilma J.M., Sunamura, Madoka, ter Hoeve, Nienke, Aernout Somsen, G., Peters, Ron J.G., Snaterse, Marjolein

“…•Patients’ risk factor perception markedly differs from their medical records.•Patients rate ‘physical inactivity’ as most applicable and important to…”
Get full text